Vivos Therapeutics (VVOS) EBIT (2020 - 2026)

Vivos Therapeutics (VVOS) has reported EBIT for 7 consecutive years, with -$4.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBIT rose 0.82% year-over-year to -$4.8 million in Q2 2026; TTM through Jun 2026 was -$22.6 million, a 58.47% decrease from a year earlier, with the FY2025 full-year figure at -$19.9 million, down 78.09% from the prior year.
• EBIT was -$4.8 million for Q2 2026 at Vivos Therapeutics, up from -$6.6 million in the prior quarter.
• Over five years, EBIT peaked at -$1.9 million in Q2 2024 and troughed at -$7.0 million in Q2 2022.
• A 5-year average of -$4.7 million and a median of -$4.8 million in 2025 frame the typical range for EBIT.
• Across the five-year window, EBIT soared 57.14% in 2024 and plunged 151.29% in 2025, its largest moves.
• Over 5 years, EBIT stood at -$6.1 million in 2022, then soared by 31.83% to -$4.1 million in 2023, then surged by 32.11% to -$2.8 million in 2024, then tumbled by 127.44% to -$6.4 million in 2025, then climbed by 24.4% to -$4.8 million in 2026.
• The last three EBIT figures came in at -$4.8 million (Q2 2026), -$6.6 million (Q1 2026), and -$6.4 million (Q4 2025), per Business Quant data.